MADISON, Wis. — On the heels of the Food and Drug Administration's approval Monday of a new drug to treat patients with Alzheimer's disease, potentially slowing down cognitive decline in patients diagnosed with it, one Wisconsin doctor who specializes in the treatment of and research into the disease found hope in the FDA's move.

"I think this is a huge day for the Alzheimer's disease field," said Dr. Nate Chin, the medical director of the Wisconsin Alzheimer's Disease Research Center at University Hospital in Madison. "It's important for patients, it's important for family members, clinicians and certainly the scientific community."

Dr. Chin, who lost his own father to Alzheimer's disease years ago, said that while medical breakthroughs in this field often take time, he's hopeful that they will soon come faster and be more impactful than in the past.

"I would say the next big breakthrough is coming sooner than what we've experienced before," Dr. Chin added. "The last approval of a drug was in 2003, so it's taken almost 20 years to get to this point, but that's because it took a long time to identify the proteins and pathology of the disease in a living person. Now that we can do that very effectively, changes are going to happen very quickly."

You can see the entire interview with Dr. Chin above.